YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance

Inflammation Research

Volumn 55, Issue 2, 2006, Pages 53-59

  Rathcke, C N ^a   Johansen, J S ^a   Vestergaard, H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CRP; Iinsulin resistance; Inflammation; Type 2 diabetes; YKL 40

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; YKL 40;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; VENOUS BLOOD;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOPROTEINS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; RANDOM ALLOCATION; STATISTICS;

EID: 33645815907     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-005-0010-8     Document Type: Article

References (69)

1. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
2. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-50.
3. Moller DE, Flier JS. Insulin resistance - mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-48.
4. DeFronzo RA, Bonadonna R, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-68.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-13.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000: 342: 836-43.
8. Festa A, D'Agostino R, Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
9. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161: 233-42.
10. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971-7.
11. Hak AE, Pols HA, Stehouwer CD et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001; 86: 4398-405.
12. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
13. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
14. Jialal I, Devaraj S. Role of C-reactive protein in the assessment of cardiovascular risk. Am J Cardiol 2003; 91: 200-2.
15. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803-10.
16. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221-5.
17. Renkema GH, Boot RG, Au FL et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998; 251: 504-9.
18. Rehli M, Niller HH, Ammon C et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003; 278: 44058-67.
19. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003; 278: 37753-60.
20. Houston DR, Recklies AD, Krupa JC, van Aalten DM. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003; 278: 30206-12.
21. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
22. Ostergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 2002; 9: 598-604.
23. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sorensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999; 180: 1722-6.
24. Volck B, Price PA, Johansen JS et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110: 351-60.
25. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 1996; 60: 540-5.
26. Baeten D, Boots AM, Steenbakkers PG et al. Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1233-43.
27. Boot RG, van Achterberg TA, van Aken BE et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 687-94.
28. Volck B, Johansen JS, Stoltenberg M et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001; 9: 203-14.
29. Johansen JS, Baslund B, Garbarsch C et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 1999; 42: 2624-30.
30. Millis AJ, Hoyle M, Reich E, Mann DM. Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J Biol Chem 1985; 260: 3754-61.
31. Millis AJ, Hoyle M, Kent L. In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 1986; 127: 366-72.
32. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995; 270: 13076-83.
33. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999; 250: 168-73.
34. Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997; 100: S87-S89.
35. Johansen JS, Stoltenberg M, Hansen M et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999; 38: 618-26.
36. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003; 287: 79-87.
37. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model asssessment: insulin resistnce and β-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
39. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975; 11: 541-8.
40. Faber OK, Marcussen J, Naithani VK, Binder C. Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin. Hoppe-Seyler's Z Physiol Chem 1976; 357: 751-7.
41. Faber O, Binder C, Markussen J et al. Characterization of seven C-peptide antisera. Diabetes 1978; 27: 170-7.
42. Lanng S, Thorsteinsson B, Røder ME et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinologica (Copenh) 1993; 128: 207-14.
43. Itaya K, Michio U. Colorimetric determination of free fatty acids in biological fluids. J Lipid Res 1965; 6: 16-20.
44. Harvey S, Weisman M, O'Dell J et al. Chondrex: new marker of joint disease. Clin Chem 1998; 44: 509-16.
45. Gray DS, Bray GA, Gemayel N, Kaplan K. Effect of obesity on bioelectrical impedance. Am J Clin Nutr 1989; 50: 255-60.
46. Kronborg G, Ostergaard C, Weis N et al. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis 2002; 34: 323-6.
47. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 599-605.
48. Vos K, Steenbakkers P, Miltenburg AM et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000; 59: 544-8.
49. Temelkova-Kurktschiev T, Siegert G, Bergmann S et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743-9.
50. Festa A, Hanley AJ, Tracy RP, D'Agostino R, Jr., Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003; 108: 1822-30.
51. Ridker PM. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81-e85.
52. Festa A, D'Agostino R, Jr., Williams K et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407-15.
53. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol 2001; 19: 655-60.
54. Nyirkos P, Golds EE. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990; 269: 265-8.
55. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14.
56. Blankenberg S, Luc G, Ducimetiere P et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-9.
57. Blankenberg S, Tiret L, Bickel C et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
58. Esposito K, Pontillo A, Di PC et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-804.
59. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004; 89: 806-11.
60. Bosch M, Lopez-Bermejo A, Vendrell J, Musri M, Ricart W, Fernandez-Real JM. Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia 2005; 48: 1841-3.
61. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
62. Cominacini L, Fratta PA, Garbin U et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995; 38: 1122-4.
63. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
64. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-10.
65. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
66. Leinonen ES, Hiukka A, Hurt-Camejo E et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med 2004; 256: 119-27.
67. Bluher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia 2002; 45: 210-6.
68. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-86.
69. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 131-8.